Alto Neuroscience (NYSE:ANRO) Stock Price Down 3.6% – Time to Sell?

Alto Neuroscience, Inc. (NYSE:ANRO) shares traded down 3.6% during mid-day trading on Tuesday . The stock traded as low as $22.76 and last traded at $23.42. 64,977 shares were traded during trading, a decline of 71% from the average session volume of 223,010 shares. The stock had previously closed at $24.29.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ANRO shares. BTIG Research boosted their price target on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Alto Neuroscience in a research report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Robert W. Baird raised their price target on Alto Neuroscience from $22.00 to $41.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Jefferies Financial Group restated a “buy” rating and issued a $35.00 price target on shares of Alto Neuroscience in a report on Monday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.33.

Alto Neuroscience Trading Up 0.9%

The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.42 and a current ratio of 15.69. The firm has a market capitalization of $720.79 million, a price-to-earnings ratio of -10.35 and a beta of 2.52. The business has a fifty day moving average price of $18.25 and a 200 day moving average price of $13.41.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. As a group, equities analysts forecast that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ANRO. Bank of Montreal Can purchased a new stake in Alto Neuroscience during the second quarter worth approximately $25,000. AlphaCore Capital LLC lifted its holdings in shares of Alto Neuroscience by 100.0% during the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $44,000 after acquiring an additional 10,000 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Alto Neuroscience during the 1st quarter valued at $52,000. Torren Management LLC purchased a new stake in Alto Neuroscience during the 4th quarter worth $62,000. Finally, Invesco Ltd. acquired a new stake in Alto Neuroscience in the 1st quarter valued at $67,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.